LOGIN
Safety & Efficacy of Imrecoxib Vs Celecoxib In Total Hip Arthroplasty: A Non-Inferiority Study
December 2023
Safety & Efficacy of Imrecoxib Vs Celecoxib In Total Hip Arthroplasty: A Non-Inferiority Study
Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:1
Postoperative analgesic efficacy and safety of imrecoxib versus celecoxib in hip osteoarthritis patients undergoing total hip arthroplasty: a multi-center, randomized, controlled, non-inferiority study.
Inflammopharmacology . 2023 Aug;31(4):1813-1822.Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
156 patients undergoing total hip arthroplasty (THA) for hip osteoarthritis were randomized to receive either celecoxib (n=78) or imrecoxib (n=78). Outcomes of interest included pain at rest and with movement on a Visual Analog Scale (VAS), opioid consumption, Harris Hip Scores (HHS), quality of life on the EuroQol 5 Dimensions (EQ-5D) questionnaire, and the incidence of adverse events, all measur...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.